Evidence map›Paper›PMID 35476257›Full record

ArticlePituitary2022

Quality of life after long-term biochemical control of acromegaly.

Allison Kimball, Laura E Dichtel, Kevin C J Yuen, Whitney W Woodmansee, Melanie S Haines, Lisa B Nachtigall, Brooke Swearingen, Pamela Jones, Nicholas A Tritos, Julie L Sharpless and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pituitary, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Trial
  3. The acromegaly patient experience: burden of treatment and quality of life.The Journal of clinical endocrinology and metabolism · 2026
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Allison KimballNeuroendocrine Unit, Massachusetts General Hospital, 55 Fruit Street, Bulfinch 457, Boston, MA, 02114, USA. akimball1@partners.org.ORCID http://orcid.org/0000-0002-6750-644X
Laura E DichtelNeuroendocrine Unit, Massachusetts General Hospital, 55 Fruit Street, Bulfinch 457, Boston, MA, 02114, USA.
Kevin C J YuenSwedish Pituitary Center, Swedish Neuroscience Institute, Seattle, WA, USA.
Whitney W WoodmanseeHarvard Medical School, Boston, MA, USA.
Melanie S HainesNeuroendocrine Unit, Massachusetts General Hospital, 55 Fruit Street, Bulfinch 457, Boston, MA, 02114, USA.
Lisa B NachtigallNeuroendocrine Unit, Massachusetts General Hospital, 55 Fruit Street, Bulfinch 457, Boston, MA, 02114, USA.
Brooke SwearingenHarvard Medical School, Boston, MA, USA.
Pamela JonesHarvard Medical School, Boston, MA, USA.
Nicholas A TritosNeuroendocrine Unit, Massachusetts General Hospital, 55 Fruit Street, Bulfinch 457, Boston, MA, 02114, USA.
Julie L SharplessDepartment of Endocrinology, University of North Carolina, Chapel Hill, NC, USA.
Ursula B KaiserHarvard Medical School, Boston, MA, USA.
Anu GerweckNeuroendocrine Unit, Massachusetts General Hospital, 55 Fruit Street, Bulfinch 457, Boston, MA, 02114, USA.
Karen K MillerNeuroendocrine Unit, Massachusetts General Hospital, 55 Fruit Street, Bulfinch 457, Boston, MA, 02114, USA.
Harvard University · USBrigham and Women's Hospital · USMassachusetts General Hospital · USBarrow Neurological Institute · USUniversity of North Carolina at Chapel Hill · US

Funding

Harvard Clinical and Translational Science CenterUL1TR001102 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2013 to 2017
$106.2M
HARVARD CLINICAL AND TRANSLATIONAL SCIENCE CENTER (UL1)UL1RR025758 · NCRR · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2008 to 2011
$91.4M
Harvard Clinical and Translational Science Center (UL1)UL1TR000170 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2012 to 2013
$31.4M
TRAINING PROGRAM IN ENDOCRINOLOGY AND DIABETEST32DK007028 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Karen K Miller · 1986 to 2026
$18.5M
Growth Hormone and Cardiovascular DiseaseK24HL092902 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI MILLER, KAREN K · 2010 to 2019
$1.6M
Relative Sarcopenia and Cardiometabolic Risk in Young Adults with ObesityK23DK115903 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI HAINES, MELANIE SCHORR · 2017 to 2021
$1.1M
The Growth Hormone and Insulin-like Growth Factor-1 Axis in Nonalcoholic Fatty Liver Disease and Nonalcoholic SteatohepatitisK23DK113220 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI DICHTEL, LAURA ELISABETH · 2017 to 2021
$1.1M
Endocrine Society Acromegaly Clinical Research Fellowship AwardNCATS NIH HHS 1UL1TR001102NCATS NIH HHS 8 UL1 TR000170NCATS NIH HHS UL1 TR000170NCATS NIH HHS UL1 TR001102NCRR NIH HHS 1 UL1 RR025758NCRR NIH HHS UL1 RR025758NHLBI NIH HHS K24 HL092902NIDDK NIH HHS K23 DK113220NIDDK NIH HHS K23 DK115903NIDDK NIH HHS T32 DK007028NIH HHS K23 DK113220NIH HHS K23DK115903NIH HHS K24 HL092902NIH HHS T32 DK007028
6 · The paper itself

Abstract

purposeTo assess long-term quality of life (QoL) in patients with sustained biochemical control of acromegaly, comparing those receiving vs not receiving pharmacotherapy (primary analysis); to assess change in QoL over time (secondary analysis).

methodsCross-sectional study, with a secondary longitudinal component, of 58 patients with biochemically controlled acromegaly. All had participated in studies assessing QoL years previously, after having undergone surgery ± radiotherapy. One cohort received medical therapy [MED (n = 33)]; the other did not [NO-MED (n = 25)]. QoL was assessed by the 36-Item-Short-Form Health Survey (SF-36), Acromegaly Quality of Life Questionnaire (AcroQoL), Gastrointestinal Quality of Life Index (GIQLI), Symptom Questionnaire, and QoL-Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA).

resultsMean (± SD) duration of biochemical control was 15.0 ± 6.4 years for MED and 20.4 ± 8.2 years for NO-MED (p = 0.007). 58% of subjects scored < 25% of normal on ≥ 1 SF-36 domain and 32% scored < 25% of normal on ≥ 4 of 8 domains. Comparing MED vs NO-MED and controlling for duration of biochemical control, there were no significant differences in QoL by SF-36, AcroQOL, GIQLI, Symptom Questionnaire, or QoL-AGHDA. Growth hormone deficiency (GHD) but not radiotherapy predicted poorer QoL. In MED, QoL improved over time in three AcroQoL domains and two GIQLI domains. In NO-MED, QoL worsened in two SF-36 domains and two Symptom Questionnaire domains; QoL-AGHDA scores also worsened in subjects with GHD.

conclusionA history of acromegaly and development of GHD, but not pharmacologic or radiotherapy, are detrimental to QoL, which remains poor over the long-term despite biochemical control.

Indexed as

AcromegalyAdultCross-Sectional StudiesGrowth HormoneHumansQuality of LifeSurveys and QuestionnairesGrowth HormoneAcromegalyGrowth hormone deficiencyQuality of lifeRadiation therapy

Identifiers

PMID35476257
PMCPMC10080999
OpenAlexW4224947600

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.